Inogen (INGN) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for May 14, 2025, with virtual participation available for shareholders.
Shareholders are encouraged to review proxy materials and vote by May 13, 2025, or May 7, 2025, for plan shares.
Voting matters and shareholder proposals
Election of three Class II director nominees: Kevin King, Mary Kay Ladone, and Kevin R.M. Smith, with board recommending a vote for all.
Ratification of Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2025.
Advisory vote to approve executive compensation for named executive officers.
Approval of the Amended and Restated 2023 Equity Incentive Plan.
Board of directors and corporate governance
Board recommends all director nominees for election to Class II positions.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Inogen
- Q2 2026 revenue up 3% to $95.1M, with strong international growth and improved EBITDA.INGN
Q2 2026 - Achieved a financial turnaround and expanded into new respiratory care markets with innovative products.INGN
Corporate presentation - Diversified platform, new products, and financial turnaround position for sustained growth.INGN
Corporate presentation - Directors, auditors, and compensation approved; board declassification amendment failed.INGN
AGM 2026 - Revenue up 3.4% to $85.1M, driven by international growth despite higher net loss.INGN
Q1 2026 - Proxy details director elections, governance reforms, and expanded equity incentives for 2026.INGN
Proxy filing - Shareholders will vote on board declassification, equity plan expansion, and key governance changes.INGN
Proxy filing - New products and leadership drive growth, margin expansion, and strategic transformation.INGN
25th Annual Needham Virtual Healthcare Conference - Diversifying into respiratory care, achieving financial turnaround, and launching innovative products.INGN
Company presentation - Diversified portfolio and innovation pipeline set to drive growth and profitability.INGN
2026 KeyBanc Capital Markets Healthcare Forum